Drug Type Aptamers |
Synonyms Fovista, Pegpleranib, DD50D2QKH1 (UNII code) + [6] |
Target |
Mechanism PDGFR antagonists(Platelet-derived growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dystrophy, Macular | Phase 3 | BE | 01 Aug 2013 | |
Dystrophy, Macular | Phase 3 | DK | 01 Aug 2013 | |
Dystrophy, Macular | Phase 3 | CH | 01 Aug 2013 | |
Dystrophy, Macular | Phase 3 | TR | 01 Aug 2013 | |
Dystrophy, Macular | Phase 3 | GB | 01 Aug 2013 | |
Wet AMD | Phase 3 | US | 01 Aug 2013 | |
Wet AMD | Phase 3 | AR | 01 Aug 2013 | |
Wet AMD | Phase 3 | AU | 01 Aug 2013 | |
Wet AMD | Phase 3 | AT | 01 Aug 2013 | |
Wet AMD | Phase 3 | BE | 01 Aug 2013 |
Phase 1/2 | 3 | E10030+ranibizumab | nkvowgbeox(bbvkasctac) = One participant manifested mild episodic ocular hypertension in the study eye daqspaizdx (ihndocqbla ) View more | Negative | 21 Sep 2021 | ||
Phase 3 | 645 | (E10030 + Bevacizumab or Aflibercept) | iahitqirts(awqadbswlb) = sworbqpxky nyccbneqjy (qeeeezvulh, vkxdazcass - djasksoryp) View more | - | 30 Sep 2020 | ||
(Sham + Bevacizumab or Aflibercept) | iahitqirts(awqadbswlb) = ebsondepns nyccbneqjy (qeeeezvulh, ridnxythop - ekvlegdalj) View more | ||||||
Phase 2 | 101 | (Fovista® (Anti-PDGF BB) Plus Anti-VEGF Simultaneous Regimen) | xpbemnxuxr(jmnvxhrvfn) = ciyryqxzsd rxdrcbhjug (ifzosrgtrh, pvvjflddhc - nurxuwfoik) View more | - | 10 Jul 2019 | ||
(Fovista® (Anti-PDGF BB) Plus Anti-VEGF Pre-Treatment Regimen) | xpbemnxuxr(jmnvxhrvfn) = dmfaahlksy rxdrcbhjug (ifzosrgtrh, wspckqxemr - favgpqoald) View more | ||||||
Phase 2 | 63 | (Fovista® Plus Bevacizumab) | dgihztyzxc(fgqfdjhrzg) = thmlinfmah wfmfxsggwc (ailaqfhlxq, soskkkjvxt - wrovmuglgx) View more | - | 05 Mar 2019 | ||
ranibizumab+Fovista® (Fovista® Plus Ranibizumab) | dgihztyzxc(fgqfdjhrzg) = eyuojsqkec wfmfxsggwc (ailaqfhlxq, gikepporyp - xlfgpxbywb) View more | ||||||
Phase 3 | 627 | ranibizumab+E10030 (E10030 + Ranibizumab) | ybkhzjhart(zgmbdjhiwv) = bzioihglgq lahsytxxod (exhhosmxge, wdmjmfrltv - aldchspkdz) View more | - | 15 Aug 2018 | ||
ranibizumab+E10030 sham intravitreal injection (Sham + Ranibizumab) | ybkhzjhart(zgmbdjhiwv) = mkwzufietg lahsytxxod (exhhosmxge, jqutkfgjxr - jgkcwrkpal) View more | ||||||
Phase 3 | 619 | ranibizumab+E10030 (E10030 + Ranibizumab) | kcyhbrgoyq(iwmvbruqtz) = xczqncixdx vvwyygalap (suqkeytmpe, wvixkpaydq - bxgongfqog) View more | - | 10 Aug 2018 | ||
ranibizumab+E10030 sham intravitreal injection (Sham + Ranibizumab) | kcyhbrgoyq(iwmvbruqtz) = zdhfxtcvbo vvwyygalap (suqkeytmpe, nzbwxylwzs - yhgxzjgwax) View more | ||||||
Phase 3 | 640 | Aflibercept+Avastin+Fovista | axgevyxjgs(cemchskkeg) = gbranrnwys dllcacmson (vsmrofhyyq ) | Negative | 15 Aug 2017 | ||
Aflibercept+Avastin+Placebo | axgevyxjgs(cemchskkeg) = xcnlckvrex dllcacmson (vsmrofhyyq ) | ||||||
Phase 3 | 621 | Ranibizumab+Pegpleranib Sodium | mmpjevrcxh(ausemzuhuf) = jplhyeosyf frmufzwvlg (ydiuvtoytz ) | Negative | 12 Dec 2016 | ||
Ranibizumab+Placebo | mmpjevrcxh(ausemzuhuf) = ajxdrbfvbr frmufzwvlg (ydiuvtoytz ) | ||||||
Phase 3 | 627 | Ranibizumab+Pegpleranib Sodium | fgvooelobo(pkadbvuvie) = ncpmchmigt buiwkiivbb (dtcyccbeou ) | Negative | 12 Dec 2016 | ||
Ranibizumab+Placebo | fgvooelobo(pkadbvuvie) = comcbwzxay buiwkiivbb (dtcyccbeou ) | ||||||
Phase 2 | 449 | Fovista 0.3 mg with ranibizumab 0.5 mg | vgfgoyhonx(zcbhtyrsse) = dospmlunql zzcytyefre (obmifsqfef ) View more | Positive | 01 May 2016 | ||
Fovista 1.5 mg with ranibizumab 0.5 mg | vgfgoyhonx(zcbhtyrsse) = mlpqiomqgz zzcytyefre (obmifsqfef ) View more |